L‐Dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys

The pharmacokinetics of levodopa (L‐dopa) in plasma and in cisternal and lumbar cerebrospinal fluid (CSF) were studied in Rhesus monkeys that were given 2‐ to 3‐hour intravenous infusions of L‐dopa. Steady‐state L‐dopa concentrations in cisternal CSF correlated well with plasma levels, and yielded a CSF: plasma ratio of 0.17. The disappearance of L‐dopa from plasma and cisternal CSF compartments fits an open, two‐compartment pharmacokinetic model. Although slower, the distribution and elimination half‐lives for L‐dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively). If cisternal CSF reflects brain extracellular fluid, then plasma pharmacokinetics of L‐dopa are a reasonable approximation of those in the brain. In contrast to cisternal CSF, the disappearance of L‐dopa from lumbar CSF fits an open, one‐compartment model with an elimination half‐life of 100 minutes. This indicates that the lumbar CSF compartment is unsuitable for investigation of the pharmacokinetics of L‐dopa in the brain.

[1]  Å. Bertler,et al.  THE DIRECT DEMONSTRATION OF A BARRIER MECHANISM IN THE BRAIN CAPILLARIES. , 2009, Acta pharmacologica et toxicologica.

[2]  J. Nutt,et al.  Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations , 1988, Neurology.

[3]  J. Nutt,et al.  3‐O‐Methyldopa and the response to levodopa in Parkinson's disease , 1987, Annals of neurology.

[4]  J. Nutt,et al.  Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients , 1987, Neurology.

[5]  T. Chase,et al.  Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease , 1987, Annals of neurology.

[6]  J. Nutt,et al.  Clinical and biochemical studies with controlled‐release levodopa/carbidopa , 1986, Neurology.

[7]  J. Nutt,et al.  Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients , 1986, Neurology.

[8]  J. Nutt,et al.  The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism , 1985, Annals of neurology.

[9]  P. Hutson,et al.  Monitoring the Effect of a Tryptophan Load on Brain Indole Metabolism in Freely Moving Rats by Simultaneous Cerebrospinal Fluid Sampling and Brain Dialysis , 1985, Journal of neurochemistry.

[10]  C. Owman,et al.  Barrier mechanisms for neutrotransmitter monoamines in the choroid plexus. , 1980, Acta physiologica Scandinavica.

[11]  I. Pye,et al.  STUDIES OF THE INTER‐RELATIONSHIP BETWEEN CEREBROSPINAL FLUID AND PLASMA AMINO ACID CONCENTRATIONS IN NORMAL INDIVIDUALS , 1977, Journal of neurochemistry.

[12]  E. Rosengren,et al.  Quantitative evaluation of the blood-brain barrier capacity to form dopamine from circulating L-DOPA. , 1977, Acta physiologica Scandinavica.

[13]  W. Pardridge.  KINETICS OF COMPETITIVE INHIBITION OF NEUTRAL AMINO ACID TRANSPORT ACROSS THE BLOOD‐BRAIN BARRIER , 1977, Journal of neurochemistry.

[14]  D. Yudilevich,et al.  Pial vessels transport of substances from cerebrospinal fluid to blood , 1974, Nature.

[15]  S. R. Snodgrass,et al.  Transport of neutral amino acids from feline cerebrospinal fluid. , 1969, American Journal of Physiology.

[16]  A. Lorenzo,et al.  AMINO ACID TRANSPORT BY CHOROID PLEXUS IN VITRO 1 , 1969, Journal of neurochemistry.

[17]  A. Lorenzo,et al.  Iodide transport from the spinal subarachnoid fluid in the cat. , 1969, The American journal of physiology.

[18]  R. Tissot,et al.  Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans. , 1967, Brain research.

[19]  M. Horne,et al.  The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study. , 1984, Pharmacology.